Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can mindfulness stop psychosis before it starts?

NCT ID NCT06870305

Prevention Sponsor: Centre Psychothérapique de Nancy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a 5-session group mindfulness program can reduce distress and prevent psychosis in 270 young people (ages 18-30) at ultra-high risk. Participants will either receive the mindfulness training plus usual care, or usual care alone. The goal is to see if mindfulness helps ease symptoms and lowers the risk of a first psychotic episode.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mindfulness-based training for psychosis (MBTP) - a group therapy program
What this could lead to
If it works, this could offer a non-drug way to reduce distress and lower the chance of developing psychosis in young people at high risk.
What could go wrong
This is an early-stage trial with no results yet. The mindfulness program is short (5 sessions over 1 month), and its long-term effects are unknown. It may not prevent psychosis for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 270 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2029

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * People aged between 18 and 30 validating the criteria for UHR or PEP status on the CAARMS scale and having a social functional impact (SOFAS score below 50 or a reduction of more than 30% in the score) Exclusion Criteria: * Previous episode of schizophrenic disorder, schizoaffective disorder or bipolar disorder * Previous antipsychotic treatment for more than 12 months * Organic mental disorder or intellectual disability * Serious suicidal/homicidal risk (but admissible if this risk has been resolved) * Insufficient French language skills * Adult incapable of giving consent and not under legal protection * Protection measure (guardianship/curatorship/court supervision) or under court supervision * Person deprived of liberty by judicial or administrative decision (including forced hospitalisation) * Persons in a life-threatening emergency * Not affiliated to a social security regime

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical high risk for psychosis (CHR) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Psychotic Disorders psychotic disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical high risk for psychosis (CHR)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire (CHU) de Brest

    Brest, 29200, France

  • Centre Psychothérapique de Nancy

    Laxou, 54520, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.